Ascelia Pharma has announced the successful completion of patient enrollment in its pivotal phase 3 clinical study, SPARKLE, with the lead candidate drug Orviglance, the company’s novel MRI contrast agent for patients with impaired kidney function.
A study presented at RSNA 2022 evaluated the effect of food intake on the absorption and signal intensity of Orviglance, a manganese-based MRI contrast agent, and successfully concluded that image enhancement is not impacted by a light meal.